These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 34388143)

  • 1. A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease.
    Cheifetz AS; Abreu MT; Afif W; Cross RK; Dubinsky MC; Loftus EV; Osterman MT; Saroufim A; Siegel CA; Yarur AJ; Melmed GY; Papamichael K
    Am J Gastroenterol; 2021 Oct; 116(10):2014-2025. PubMed ID: 34388143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.
    Papamichael K; Cheifetz AS; Melmed GY; Irving PM; Vande Casteele N; Kozuch PL; Raffals LE; Baidoo L; Bressler B; Devlin SM; Jones J; Kaplan GG; Sparrow MP; Velayos FS; Ullman T; Siegel CA
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1655-1668.e3. PubMed ID: 30928454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases.
    Mitrev N; Vande Casteele N; Seow CH; Andrews JM; Connor SJ; Moore GT; Barclay M; Begun J; Bryant R; Chan W; Corte C; Ghaly S; Lemberg DA; Kariyawasam V; Lewindon P; Martin J; Mountifield R; Radford-Smith G; Slobodian P; Sparrow M; Toong C; van Langenberg D; Ward MG; Leong RW;
    Aliment Pharmacol Ther; 2017 Dec; 46(11-12):1037-1053. PubMed ID: 29027257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of biologics for inflammatory bowel disease in Hong Kong: consensus statement.
    Leung WK; Ng SC; Chow DK; Lao WC; Leung VK; Li MK; Hui YT; Ng SS; Hui AJ; Lai ST; Lam JT; Poon JT; Chan AO; Yuen H; Wu JC; ;
    Hong Kong Med J; 2013 Feb; 19(1):61-8. PubMed ID: 23378357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Drug Monitoring to Guide Clinical Decision Making in Inflammatory Bowel Disease Patients with Loss of Response to Anti-TNF: A Delphi Technique-Based Consensus.
    Greuter T; Maillard MH; Juillerat P; Michetti P; Seibold F; Mottet C; Zahnd N; Sauter B; Schoepfer AM; Rogler G; Vavricka SR;
    Digestion; 2020; 101(6):683-691. PubMed ID: 31461706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wide variation in the use and understanding of therapeutic drug monitoring for anti-TNF agents in inflammatory bowel disease: an inexact science?
    Samaan MA; Arkir Z; Ahmad T; Irving PM
    Expert Opin Biol Ther; 2018 Dec; 18(12):1271-1279. PubMed ID: 30339466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology.
    Papamichael K; Cheifetz AS
    Curr Opin Rheumatol; 2020 Jul; 32(4):371-379. PubMed ID: 32412995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases.
    Papamichael K; Vogelzang EH; Lambert J; Wolbink G; Cheifetz AS
    Expert Rev Clin Immunol; 2019 Aug; 15(8):837-848. PubMed ID: 31180729
    [No Abstract]   [Full Text] [Related]  

  • 9. Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug?
    Papamichael K; Cheifetz AS
    Curr Opin Gastroenterol; 2019 Jul; 35(4):302-310. PubMed ID: 30973355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease.
    Carman N; Mack DR; Benchimol EI
    Curr Gastroenterol Rep; 2018 Apr; 20(5):18. PubMed ID: 29623442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic Drug Monitoring of Biologics for Patients with Inflammatory Bowel Diseases: How, When, and for Whom?
    Wu JF
    Gut Liver; 2022 Jul; 16(4):515-524. PubMed ID: 34670875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-Tumor Necrosis Factor Alpha Therapeutic Drug Monitoring in Inflammatory Disease: A Systematic Review.
    Schneider C; Stratman S; Choragudi S; Lev-Tov H
    J Drugs Dermatol; 2023 May; 22(5):445-450. PubMed ID: 37133467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia.
    Bjørlykke KH; Jahnsen J; Brynskov J; Molander P; Eberhardson M; Davidsdottir LG; Sipponen T; Hjortswang H; Goll GL; Syversen SW; Langholz E; Jørgensen KK; Steenholdt C
    Scand J Gastroenterol; 2023 Jan; 58(1):25-33. PubMed ID: 35996928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Survey Study of Gastroenterologists' Attitudes and Barriers Toward Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease.
    Grossberg LB; Papamichael K; Feuerstein JD; Siegel CA; Ullman TA; Cheifetz AS
    Inflamm Bowel Dis; 2017 Dec; 24(1):191-197. PubMed ID: 29272486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease: An Answer to Optimized Treatment?
    Hoseyni H; Xu Y; Zhou H
    J Clin Pharmacol; 2018 Jul; 58(7):864-876. PubMed ID: 29462502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Drug Monitoring in Pediatric IBD: Current Application and Future Perspectives.
    Lega S; Bramuzzo M; Dubinsky MC
    Curr Med Chem; 2018; 25(24):2840-2854. PubMed ID: 28901267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases.
    Papamichael K; Stocco G; Ruiz Del Agua A
    Ther Drug Monit; 2023 Oct; 45(5):579-590. PubMed ID: 37012629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring.
    Albader F; Golovics PA; Gonczi L; Bessissow T; Afif W; Lakatos PL
    World J Gastroenterol; 2021 Oct; 27(37):6231-6247. PubMed ID: 34712029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease.
    Papamichael K; Juncadella A; Wong D; Rakowsky S; Sattler LA; Campbell JP; Vaughn BP; Cheifetz AS
    J Crohns Colitis; 2019 Aug; 13(8):976-981. PubMed ID: 30689771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives.
    Papamichael K; Afif W; Drobne D; Dubinsky MC; Ferrante M; Irving PM; Kamperidis N; Kobayashi T; Kotze PG; Lambert J; Noor NM; Roblin X; Roda G; Vande Casteele N; Yarur AJ; Arebi N; Danese S; Paul S; Sandborn WJ; Vermeire S; Cheifetz AS; Peyrin-Biroulet L;
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):171-185. PubMed ID: 35026171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.